Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback